Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses

Journal of Virology

Volumn 88, Issue 3, 2014, Pages 1771-1780

  Phillips, Aaron T ^a   Schountz, Tony ^a   Toth, Ann M ^b   Rico, Amber B ^a   Jarvis, Donald L ^b   Powers, Ann M ^c   Olson, Ken E ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF WYOMING   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATIONIC LIPID NUCLEIC ACID COMPLEX; GLYCOPROTEIN E1; LIPOSOME ANTIGEN NUCLEIC ACID COMPLEX; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ALPHAVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CULEX; CULEX TARSALIS; DRUG EFFICACY; EASTERN EQUINE ENCEPHALOMYELITIS VIRUS; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SURVIVAL; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ENCEPHALITIS VIRUS, EASTERN EQUINE; ENCEPHALITIS VIRUS, WESTERN EQUINE; ENCEPHALOMYELITIS, EQUINE; FEMALE; HUMANS; IMMUNIZATION; LIPOSOMES; MICE; NUCLEIC ACIDS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84892453784     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02297-13     Document Type: Article

References (42)

1. Ryman KD, Klimstra WB. 2008. Host responses to alphavirus infection. Immunol. Rev. 225:27-45. http://dx.doi.org/10.1111/j.1600-065X.2008 .00670.x.
2. Pittman PR. 1999. Immunization of persons at risk of exposure to eastern equine encephalitis virus: continued assessment of the safety and effectiveness of eastern equine encephalitis vaccine, inactivated, TSI-GSD 104 (protocol no. IND 266:FY99-11). U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD.
3. Reisler RB, Gibbs PH, Danner DK, Boudreau EF. 2012. Immune interference in the setting of same-day administration of two similar inactivated alphavirus vaccines: eastern equine and western equine encephalitis. Vaccine 30:7271-7277. http://dx.doi.org/10.1016/j.vaccine.2012.09.049.
4. Strizki JM, Repik PM. 1995. Differential reactivity of immune sera from human vaccinees with field strains of eastern equine encephalitis virus. Am. J. Trop. Med. Hyg. 53:564-570.
5. Engler RJ, Mangiafico JA, Jahrling P, Ksiazek TG, Pedrotti-Krueger M, Peters CJ. 1992. Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine. J. medical virology 38:305-310. http://dx.doi.org/10.1002/jmv.1890380414.
6. Das D, Gares SL, Nagata LP, Suresh MR. 2004. Evaluation of a western equine encephalitis recombinant E1 protein for protective immunity and diagnostics. Antiviral Res. 64:85-92. http://dx.doi.org/10.1016/S0166-3542(04)00126-3.
7. Gauci PJ, Wu JQ, Rayner GA, Barabe ND, Nagata LP, Proll DF. 2010. Identification of Western equine encephalitis virus structural proteins that confer protection after DNA vaccination. Clin. Vaccine Immunol. 17:176-179. http://dx.doi.org/10.1128/CVI.00377-09.
8. Wu JQ, Barabe ND, Chau D, Wong C, Rayner GR, Hu WG, Nagata LP. 2007. Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine. Vaccine 25:4368-4375. http://dx.doi.org/10.1016/j.vaccine.2007.03 .042.
9. Hahn CS, Lustig S, Strauss EG, Strauss JH. 1988. Western equine encephalitis virus is a recombinant virus. Proc. Natl. Acad. Sci. U.S.A. 85:5997-6001. http://dx.doi.org/10.1073/pnas.85.16.5997.
10. Netolitzky DJ, Schmaltz FL, Parker MD, Rayner GA, Fisher GR, Trent DW, Bader DE, Nagata LP. 2000. Complete genomic RNA sequence of western equine encephalitis virus and expression of the structural genes. J. Gen. Virol. 81:151-159.
11. Schmaljohn AL, Johnson ED, Dalrymple JM, Cole GA. 1982. Nonneutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 297:70-72. http://dx.doi.org/10.1038/297070a0.
12. Julander JG, Siddharthan V, Blatt LM, Schafer K, Sidwell RW, Morrey JD. 2007. Effect of exogenous interferon and an interferon inducer on western equine encephalitis virus disease in a hamster model. Virology 360:454-460. http://dx.doi.org/10.1016/j.virol.2006.10.031.
13. Logue CH, Phillips AT, Mossel EC, Ledermann JP, Welte T, Dow SW, Olson KE, Powers AM. 2010. Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge. Antiviral Res. 87:195-203. http://dx.doi.org/10.1016/j.antiviral.2010.04.013.
14. Patterson M, Poussard A, Taylor K, Seregin A, Smith J, Peng BH, Walker A, Linde J, Smith J, Salazar M, Paessler S. 2011. Rapid, noninvasive imaging of alphaviral brain infection: reducing animal numbers and morbidity to identify efficacy of potential vaccines and antivirals. Vaccine 29:9345-9351. http://dx.doi.org/10.1016/j.vaccine.2011.09.130.
15. Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, Soundarapandian V, Ahumada A, Keler T, Hoffman SL, Nussenzweig MC, Steinman RM, Seder RA. 2010. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDECFIG CSP in non human primates. Vaccine 28:7256-7266. http://dx.doi.org/10 .1016/j.vaccine.2010.08.098.
16. Kumar H, Koyama S, Ishii KJ, Kawai T, Akira S. 2008. Cutting edge: cooperation of IPS-1-and TRIF-dependent pathways in poly ICenhanced antibody production and cytotoxic T cell responses. J. Immunol. 180:683-687.
17. Sloat BR, Cui Z. 2006. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm. Res. 23:1217-1226. http://dx.doi.org/10.1007/s11095-006-0206-9.
18. von Hunolstein C, Mariotti S, Teloni R, Alfarone G, Romagnoli G, Orefici G, Nisini R. 2001. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anticarrier polyvalent vaccines. Vaccine 19:3058-3066. http://dx.doi.org/10 .1016/S0264-410X(01)00048-2.
19. Xie H, Gursel I, Ivins BE, Singh M, O'Hagan DT, Ulmer JB, Klinman DM. 2005. CpG oligodeoxynucleotides adsorbed onto polylactidecoglycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun. 73:828-833. http://dx.doi.org/10.1128/IAI.73.2.828-833.2005.
20. Fogg CN, Americo JL, Lustig S, Huggins JW, Smith SK, Damon I, Resch W, Earl PL, Klinman DM, Moss B. 2007. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 25:2787-2799. http://dx .doi.org/10.1016/j.vaccine.2006.12.037.
21. Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, Turner RR, Faries MB. 2012. Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. J. Immunother. 35:716-720. http://dx.doi.org/10.1097/CJI.0b013e31827457bd.
22. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, Garcia-Sastre A, Compans R, Pulendran B. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470:543-547. http://dx.doi.org/10.1038/nature09737.
23. Kawai T, Akira S. 2007. Antiviral signaling through pattern recognition receptors. J. Biochem. 141:137-145. http://dx.doi.org/10.1093/jb/mvm032.
24. Phillips AT, Stauft CB, Aboellail TA, Toth AM, Jarvis DL, Powers AM, Olson KE. 2013. Bioluminescent imaging and histopathologic characterization of WEEV neuroinvasion in outbred CD-1 mice. PLoS One 8:2. http://dx.doi.org/10.1371/journal.pone.0053462.
25. Wang E, Petrakova O, Adams AP, Aguilar PV, Kang W, Paessler S, Volk SM, Frolov I, Weaver SC. 2007. Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice. Vaccine 25:7573-7581. http://dx.doi.org/10.1016/j.vaccine.2007.07 .061.
26. Logue CH, Bosio CF, Welte T, Keene KM, Ledermann JP, Phillips A, Sheahan BJ, Pierro DJ, Marlenee N, Brault AC, Bosio CM, Singh AJ, Powers AM, Olson KE. 2009. Virulence variation among isolates of western equine encephalitis virus in an outbred mouse model. J. Gen. Virol. 90:1848-1858. http://dx.doi.org/10.1099/vir.0.008656-0.
27. Mossel EC, Ledermann JP, Phillips AT, Borland EM, Powers AM, Olson KE. 2013. Molecular determinants of mouse neurovirulence and mosquito infection for Western equine encephalitis virus. PLoS One 8:e60427. http://dx.doi.org/10.1371/journal.pone.0060427.
28. Toth AM, Geisler C, Aumiller JJ, Jarvis DL. 2011. Factors affecting recombinant Western equine encephalitis virus glycoprotein production in the baculovirus system. Protein Expr. Purif. 80:274-282. http://dx.doi .org/10.1016/j.pep.2011.08.002.
29. Cutchins E, Warren J, Jones WP. 1960. The antibody response to smallpox vaccination as measured by a tissue culture plaque method. J. Immunol. 85:275-283.
30. Gowen BB, Fairman J, Smee DF, Wong MH, Jung KH, Pace AM, Heiner ML, Bailey KW, Dow SW, Sidwell RW. 2006. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res. 69:165-172. http://dx.doi.org/10.1016/j.antiviral.2005.12.002.
31. Morrey JD, Motter NE, Taro B, Lay M, Fairman J. 2008. Efficacy of cationic lipid-DNA complexes (CLDC) on hepatitis B virus in transgenic mice. Antiviral Res. 79:71-79. http://dx.doi.org/10.1016/j.antiviral.2008 .01.157.
32. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, Diamond MS, Colonna M. 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. U.S.A. 103:8459-8464. http://dx.doi.org/10.1073/pnas.0603082103.
33. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O, Akira S. 2005. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23: 19-28. http://dx.doi.org/10.1016/j.immuni.2005.04.010.
34. Zou J, Kawai T, Tsuchida T, Kozaki T, Tanaka H, Shin KS, Kumar H, Akira S. 2013. Poly IC triggers a cathepsin D-and IPS-1-dependent pathway to enhance cytokine production and mediate dendritic cell necroptosis. Immunity 38:717-728. http://dx.doi.org/10.1016/j.immuni.2012.12 .007.
35. Stec DS, Waddell A, Schmaljohn CS, Cole GA, Schmaljohn AL. 1986. Antibody-selected variation and reversion in Sindbis virus neutralization epitopes. J. Virol. 57:715-720.
36. Hunt AR, Roehrig JT. 1985. Biochemical and biological characteristics of epitopes on the E1 glycoprotein of western equine encephalitis virus. Virology 142:334-346. http://dx.doi.org/10.1016/0042-6822(85)90342-3.
37. Roehrig JT. 1993. Immunogens of encephalitis viruses. Vet. Microbiol. 37:273-284. http://dx.doi.org/10.1016/0378-1135(93)90029-7.
38. Roehrig JT, Bolin RA. 1997. Monoclonal antibodies capable of distinguishing epizootic from enzootic varieties of subtype 1 Venezuelan equine encephalitis viruses in a rapid indirect immunofluorescence assay. J. Clin. Microbiol. 35:1887-1890.
39. Burdeinick-Kerr R, Wind J, Griffin DE. 2007. Synergistic roles of antibody and interferon in noncytolytic clearance of Sindbis virus from different regions of the central nervous system. J. Virol. 81:5628-5636. http://dx.doi.org/10.1128/JVI.01152-06.
40. Griffin D, Levine B, Tyor W, Ubol S, Despres P. 1997. The role of antibody in recovery from alphavirus encephalitis. Immunol. Rev. 159: 155-161. http://dx.doi.org/10.1111/j.1600-065X.1997.tb01013.x.
41. Metcalf TU, Baxter VK, Nilaratanakul V, Griffin DE. 2013. Recruitment and retention of B cells in the central nervous system in response to alphavirus encephalomyelitis. J. Virol. 87:2420-2429. http://dx.doi.org/10 .1128/JVI.01769-12.
42. Snapper CM, Paul WE. 1987. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236:944-947. http://dx.doi.org/10.1126/science.3107127.